论文部分内容阅读
目的:评价用布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗婴幼儿哮喘的临床疗效。方法:采用随机分组方法,将2010年3月—2013年6月间萍乡市妇幼保健院儿科门诊内收治的确诊96例婴幼儿哮喘患者,分为观察组(48例),给予布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗,对照组(48例),给予常规方法治疗;将治疗前后的临床症状消失时间、临床疗效及不良反应情况等做一比较,并回顾性分析两组患儿的临床资料。结果:治疗后,观察组总有效率91.67%与对照组总有效率79.17%比较,其差异有统计学意义(P<0.05),观察组咳嗽,憋喘及肺部哮鸣音等临床症状的缓解或消失时间皆短于对照组(P<0.05),两组患儿均未发生不良反应。结论:用布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗婴幼儿哮喘,其疗效较显著,不良反应较少,安全性较高,值得临床使用。
OBJECTIVE: To evaluate the clinical efficacy of budesonide suspension combined with ipratropium bromide in the treatment of infantile asthma. Methods: Ninety-six infants and young children diagnosed as infantile asthma admitted in Pediatric Outpatient Department of Pingxiang MCH from March 2010 to June 2013 were randomly divided into observation group (48 cases), budesonide mixed The control group (n = 48) was given routine treatment. The time of disappearance of clinical symptoms, clinical efficacy and adverse reactions before and after treatment were compared and retrospectively analyzed Clinical data of two groups of children. Results: After treatment, the total effective rate in the observation group was 91.67% compared with the total effective rate in the control group (79.17%), the difference was statistically significant (P <0.05). The clinical symptoms of cough, wheezing and wheezing in the observation group Alleviating or disappearing time were shorter than the control group (P <0.05), no adverse reactions in both groups of children. Conclusion: The combination of budesonide suspension and compound ipratropium bromide inhalation for the treatment of infantile asthma has obvious curative effect, less adverse reactions and higher safety, which is worth to be used clinically.